Drug Trial Radar · NCT06904872
Safety and Efficacy of Crofelemer in Adult Patients With Short Bowel Syndrome and Intestinal Failure (SBS-IF) Without Colon-in-continuity (CIC)
Last checked: Nov 20, 2026Latest source record: Jun 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
18
Planned (sponsor's estimate)
Start
May 29, 2025
Primary completion
Mar 2027
Study completion Mar 2027
Sponsor
- Lead sponsor
- Napo Therapeutics, S.p.A.Industry
- Sponsor type
- Industry
- First posted
- Apr 1, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A 24-week, randomized, placebo-controlled, double-blind study to evaluate the efficacy, safety and tolerability of crofelemer in patients with Short Bowel Syndrome and Intestinal Failure (SBS-IF) without colon-in-continuity (CIC) requiring parenteral support (PS). Blinded study drug will be administered orally (or enterally) three times daily (TID) as a novel crofelemer formulation, Crofelemer Powder for Oral Solution, or a matching placebo powder formulation for oral solution. Patients will be randomized in a 1:1:1 ratio to crofelemer 3 mg/kg/dose TID, crofelemer 10 mg/kg/dose TID or placebo.
Conditions
- Short Bowel Syndrome
- Malabsorption Syndromes
- Short Gut Syndrome
- Post-Op Complication
- Functional Gastrointestinal Disorders
Interventions
Crofelemer Powder for Oral SolutionDrug
Crofelemer Powder for Oral Solution
Matched Placebo Powder for Oral SolutionDrug
Matched Placebo Powder for Oral Solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and TolerabilityTime frame: 24 weeks
- Safety and TolerabilityTime frame: 24 weeks
- Preliminary EfficacyTime frame: 24 weeks
- Preliminary EfficacyTime frame: 24 weeks
Locations
8 sites in 2 countries. Site status is shown where the registry gives one.
Universitäatsklinik RWTH
Aachen, Germany · Recruiting
Charité Universitätsmedizin
Berlin, Germany · Recruiting
Universitätsklinikum
Essen, Germany · Recruiting
Asklepios Klinik St. Georg
Hamburg, Germany · Recruiting
Universitätsmedizin
Rostock, Germany · Recruiting
Azienda Ospedaliero-Universitaria di Bologna Policlinico S. Orsola-Malpighi
Bologna, Italy · Recruiting
Azienda Ospedaliera Universitaria Federico II
Naples, Italy · Recruiting
Ospedale Università di Padova
Padova, Italy · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.